Ibandronate

Breast Cancer

Azienda Ospedaliero-Universitaria CareggiSmall moleculePhase 3Dormant

B

62/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 63/ 100
Competitive Position: 59/ 100

Competitive context

849 Active assets in the Breast Cancer cohort.

Asset / Sponsor	Phase	Rating
Darolutamide Vandana Abramson	Phase 2	BBB
Palbociclib Hoffmann-La Roche	Phase 4	BB
Ribociclib National Cancer Institute (NCI)	Phase 4	BB
Trastuzumab Duocarmazine Byondis B.V.	Phase 3	BB
VITAMIN D University of Illinois at Chicago	Phase 4	BB

View all 50 →

Same molecule, other indications

Ibandronate is also rated in:

metastatic carcinoma in the boneDormant

BBB

Indicative ·

79 / 100

PainDormant

BB

Indicative ·

64 / 100

metastatic malignant neoplasmDormant

B

Indicative ·

62 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.